Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 4:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–40 of 40 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: BIC Clear all
Recruiting Not applicable Interventional

Motor Recovery Through Plasticity-Inducing Cortical Stimulation

NCT06506279
View directory record Official record
Conditions
Stroke, Ischemic
Interventions
CorTec Brain Interchange (BIC) System
Device
Lead sponsor
University of Washington
Other
Eligibility
22 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Completed Phase 4 Interventional Results available

Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant

NCT04530630
View directory record Official record
Conditions
HIV Infections, Renal Transplant Rejection
Interventions
BIC/F/TAF 50Mg-200Mg-25Mg Tablet
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 18, 2026, 4:59 AM EDT
Completed Phase 3 Interventional Results available

A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition

NCT01557244
View directory record Official record
Conditions
Urinary Bladder, Neurogenic
Interventions
Fesoterodine PR 4 mg, Fesoterodine PR 8 mg, Oxybutynin, Fesoterodine PR, Fesoterodine BIC 2 mg, Fesoterodine BIC 4 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
18
States / cities
Tucson, Arizona • Orange, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 18, 2026, 4:59 AM EDT
Recruiting Phase 4 Interventional

REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE

NCT07476339
View directory record Official record
Conditions
HIV -1 Infection, HIV (Human Immunodeficiency Virus), HIV, HIV 1 Infection
Interventions
Bictegravir, emtricitabine, and tenofovir alafenamide
Drug
Lead sponsor
CAN Community Health
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Clearwater, Florida • Ft. Pierce, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1

NCT02881320
View directory record Official record
Conditions
HIV-1 Infection
Interventions
B/F/TAF (Adult Strength), B/F/TAF (Low Dose), B/F/TAF (TOS)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
1 Month to 17 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Ft. Pierce, Florida • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

NCT04542070
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Tablets, Cabotegravir Injectable Suspension (CAB LA), Rilpivirine Tablets, Rilpivirine Injectable Suspension (RPV LA), BIKTARVY Tablets (BIK)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
41
States / cities
Bakersfield, California • Beverly Hills, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 18, 2026, 4:59 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

NCT07266831
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Interventions
ISL, ULO, BIC/FTC/TAF, Placebo for BIC/FTC/TAF, Placebo to ISL/ULO, ISL/ULO
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
24
States / cities
Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Multi-College Bystander Efficacy Evaluation

NCT02659423
View directory record Official record
Conditions
Sexual Violence
Interventions
BIC 1, BIC 2, BIC 3
Behavioral
Lead sponsor
Ann Coker
Other
Eligibility
18 Years to 24 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Oct 18, 2026, 4:59 AM EDT
Completed Phase 4 Interventional

Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1

NCT03502005
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
bictegravir/emtricitabine/tenofovir alafenamide
Drug
Lead sponsor
Midland Research Group, Inc.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Oakland Park, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 18, 2026, 4:59 AM EDT
Terminated Phase 2 Interventional Results available

Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy

NCT06005610
View directory record Official record
Conditions
HIV I Infection
Interventions
Estradiol
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Male only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
14
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Affordable Mobile Robots for the Elderly

NCT02807506
View directory record Official record
Conditions
Aging
Interventions
Mobile Service Robot, Survey
Device · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 18, 2026, 4:59 AM EDT
Completed Not applicable Interventional

Impact of Rapid ART Initiation on Retention in Care in the Southern US

NCT04266938
View directory record Official record
Conditions
HIV-1-infection
Interventions
Rapid start of antiretrovirals, Retrospective analysis, Non- RAPID start
Behavioral
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 18, 2026, 4:59 AM EDT
Active, not recruiting Not applicable Interventional Results available

Acute Recording of Stereotyped High-Frequency Oscillations

NCT05439655
View directory record Official record
Conditions
Epilepsy
Interventions
Brain Interchange System
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
3 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

NCT05911360
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
DTG/3TC
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
50 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
24
States / cities
Phoenix, Arizona • Bakersfield, California • Palm Springs, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

NCT05705349
View directory record Official record
Conditions
HIV-1 Infection
Interventions
DOR/ISL, BIC/FTC/TAF, Placebo to DOR/ISL, Placebo to BIC/FTC/TAF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
537 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
38
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 18, 2026, 4:59 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Tennessee Youth Prepared for Success

NCT06001892
View directory record Official record
Conditions
Adolescent Behavior, Adolescent Problem Behavior, Risk Reduction
Interventions
Tennessee Youth Prepared for Success
Behavioral
Lead sponsor
Centerstone Research Institute
Other
Eligibility
14 Years to 19 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 18, 2026, 4:59 AM EDT